Anthon Jahreskog

This profile gathers the share dealings of Anthon Jahreskog in Infant Bacterial Therapeutics. Between 29 June 2021 and 2 September 2024, the trades on record add up to 24 filings.

No open-market sale appears; the market trades are 22 purchases worth €93k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2024, the count stands at 14 purchases and no sales.

Half of the purchases are above €2,332 and half below. Clusters matter here: 9 out of 22 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The record was last updated on 3 September 2024 with an open-market purchase (€24k) in Infant Bacterial Therapeutics. Half of the filings or more reach the Finansinspektionen feed on the day of the trade. The legal deadline for notifying a trade is three business days (MAR article 19). Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.